Needham & Company Reiterates Buy Rating on Establishment Labs

Establishment Labs Holdings Inc. (NASDAQ: ESTA) received a renewed “buy” rating from analysts at Needham & Company LLC, as detailed in a research note released on Monday. The firm set a target price of $84.00 for the stock, indicating a potential upside of 26.39% based on its previous closing price.

Several other research firms have also provided assessments of Establishment Labs recently. For instance, Weiss Ratings maintained a “sell (e+)” rating on the company’s shares on December 29, while BTIG Research increased its price target from $81.00 to $86.00 and reaffirmed a “buy” rating on December 31. Additionally, Mizuho raised its target from $85.00 to $90.00 and assigned an “outperform” rating on December 17. Wall Street Zen upgraded the stock from “sell” to “hold” on October 19, and Citigroup adjusted its target from $62.00 to $75.00, labeling it as “neutral” on December 11.

Currently, six analysts have rated Establishment Labs with a “buy,” one has a “hold,” and one has issued a “sell” rating. According to data from MarketBeat.com, the average rating for the stock stands at “Moderate Buy,” with a consensus target price of $78.86.

Quarterly Earnings Performance

Establishment Labs reported its quarterly earnings on November 5, 2023. The company posted an earnings per share (EPS) of ($0.38), surpassing analysts’ expectations of ($0.54) by $0.16. Revenue for the quarter was $53.78 million, exceeding the consensus estimate of $52.28 million. Year over year, revenue increased by 33.8%. In the same quarter of the previous year, the company reported an EPS of ($0.59). Analysts project that Establishment Labs will report an EPS of ($2.41) for the current year.

Despite these positive earnings results, the company faced challenges with a negative return on equity of 235.45% and a negative net margin of 43.45%.

Institutional Investor Activity

Recent trading activity indicates notable changes among institutional investors in Establishment Labs. Quarry LP acquired a new stake during the third quarter, valued at approximately $34,000, while the State of Wyoming also purchased a new stake worth around $71,000 in the same period. Osaic Holdings Inc. made a significant move by increasing its stake by 900.0% in the second quarter, now holding 2,000 shares valued at $85,000 after acquiring an additional 1,800 shares.

CWM LLC raised its position in Establishment Labs by 45.9% during the second quarter, now owning 2,182 shares valued at $93,000. PharVision Advisers LLC also entered the fray by purchasing a new position in the third quarter valued at approximately $203,000. Institutional investors collectively own 72.91% of the company’s stock, reflecting significant confidence in Establishment Labs’ future prospects.

Establishment Labs is a global medical technology company specializing in the design and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. Its flagship products fall under the Motiva® brand, showcasing innovations aimed at enhancing surgical outcomes and supporting clinical traceability. The company continues to focus on patient safety and customization, which are central to its product offerings.